PMID- 38492281
OWN - NLM
STAT- MEDLINE
DCOM- 20240427
LR  - 20240427
IS  - 1535-6345 (Electronic)
IS  - 0147-0272 (Linking)
VI  - 49
DP  - 2024 Apr
TI  - Development and validation of nomogram models for predicting postoperative 
      prognosis of early-stage laryngeal squamous cell carcinoma.
PG  - 101079
LID - S0147-0272(24)00020-5 [pii]
LID - 10.1016/j.currproblcancer.2024.101079 [doi]
AB  - BACKGROUND: We aimed to investigate the postoperative prognosis in patients with 
      early-stage laryngeal squamous cell carcinoma (LSCC) in association with the 
      preoperative blood markers and clinicopathological characteristics and to develop 
      nomograms for individual risk prediction. METHODS: The clinical data of 353 
      patients with confirmed early-stage LSCC between 2009 and 2018 were 
      retrospectively retrieved from the First Affiliated Hospital with Nanjing Medical 
      University. All patients were randomly divided into the training and testing 
      groups in a 7:3 ratio. Univariate and multivariate analyses were performed, 
      followed by the construction of nomograms to predict recurrence-free survival 
      (RFS) and overall survival (OS). Finally, the nomograms were verified internally, 
      and the predictive capability of the nomograms was evaluated and compared with 
      that of tumour T staging. RESULTS: Univariate and multivariate analyses 
      identified platelet counts (PLT), fibrinogen (FIB), and platelet to lymphocyte 
      ratio (PLR) were independent factors for RFS, and FIB, systemic 
      immune-inflammation index (SII), and haemoglobin (HGB) were independent 
      prognostic factors for OS. The nomograms showed higher predictive C-indexes than 
      T staging. Furthermore, decision curve analysis (DCA) revealed that the net 
      benefit of the nomograms' calculation model was superior to that of T staging. 
      CONCLUSIONS: We established and validated nomograms to predict postoperative 1-, 
      3- and 5-year RFS and OS in patients with early-stage LSCC based on significant 
      blood markers and clinicopathological characteristics. These models might help 
      clinicians make personalized treatment decisions.
CI  - Copyright (c) 2024. Published by Elsevier Inc.
FAU - Juan, Xu
AU  - Juan X
AD  - Department of Otorhinolaryngology, The First Affiliated Hospital, Nanjing Medical 
      University, Nanjing, Jiangsu, China; Department of Otorhinolaryngology-Head and 
      Neck surgery, Shanghai Pudong New Area People's Hospital, Shanghai, China.
FAU - Jiali, Huang
AU  - Jiali H
AD  - Department of Otorhinolaryngology, The First Affiliated Hospital, Nanjing Medical 
      University, Nanjing, Jiangsu, China.
FAU - Ziqi, Liu
AU  - Ziqi L
AD  - Department of Otorhinolaryngology, The First Affiliated Hospital, Nanjing Medical 
      University, Nanjing, Jiangsu, China.
FAU - Liqing, Zhang
AU  - Liqing Z
AD  - Department of Otorhinolaryngology, The First Affiliated Hospital, Nanjing Medical 
      University, Nanjing, Jiangsu, China.
FAU - Han, Zhou
AU  - Han Z
AD  - Department of Otorhinolaryngology, The First Affiliated Hospital, Nanjing Medical 
      University, Nanjing, Jiangsu, China. Electronic address: zhouhan@jsph.org.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Validation Study
DEP - 20240315
PL  - United States
TA  - Curr Probl Cancer
JT  - Current problems in cancer
JID - 7702986
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Humans
MH  - *Nomograms
MH  - Male
MH  - Female
MH  - Middle Aged
MH  - *Laryngeal Neoplasms/surgery/pathology/blood/mortality
MH  - Retrospective Studies
MH  - Prognosis
MH  - Neoplasm Staging
MH  - Squamous Cell Carcinoma of Head and Neck/surgery/pathology/blood/mortality
MH  - Aged
MH  - Survival Rate
MH  - Follow-Up Studies
MH  - Adult
MH  - Biomarkers, Tumor/blood
OTO - NOTNLM
OT  - Early-Stage laryngeal squamous cell carcinoma
OT  - Nomogram
OT  - Overall survival
OT  - Prognosis
OT  - Recurrence-free survival
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2024/03/17 00:42
MHDA- 2024/04/28 07:24
CRDT- 2024/03/16 19:02
PHST- 2023/07/09 00:00 [received]
PHST- 2024/01/17 00:00 [revised]
PHST- 2024/03/05 00:00 [accepted]
PHST- 2024/04/28 07:24 [medline]
PHST- 2024/03/17 00:42 [pubmed]
PHST- 2024/03/16 19:02 [entrez]
AID - S0147-0272(24)00020-5 [pii]
AID - 10.1016/j.currproblcancer.2024.101079 [doi]
PST - ppublish
SO  - Curr Probl Cancer. 2024 Apr;49:101079. doi: 
      10.1016/j.currproblcancer.2024.101079. Epub 2024 Mar 15.